Sialic acid pharmaceutical-grade API is supplied as a white to off-white crystalline powder. The direct compression route is considered only after a pre-formulation screen confirms free moisture below 0.5% after drying at 40°C for 24 h. N-acetylneuraminic acid is a weak acid with pKa near 2.6, molecular weight 309.27 g/mol, and CAS registry number 131-48-6. The free carboxyl group contributes to punch filming when press feed-frame humidity exceeds 40% RH. Pilot-scale rotary compaction trials on a 16-station B-tooling press show that material with D50 below 45 µm creates die-fill variability above 3.0% RSD. A direct compression grade with D50 between 75 µm and 150 µm is therefore preferred for pharmaceutical tablet manufacture. The blend begins with a 1:1 pre-mix of sialic acid and mannitol. Microcrystalline cellulose is added to bring the API loading to 25–35 wt%. Crospovidone is used at 2.0–4.0 wt% to maintain disintegration performance. Magnesium stearate is added last at 0.5–1.0 wt% after the lubricant-free blend completes 150 rotations in a bin blender. Compression force is limited to 7–12 kN because tablets compressed above 12 kN show lamination under friability testing. Target tablet hardness is 60–90 N and friability is less than 1.0% by USP <1216>. Content uniformity is assessed by USP <905>. Dissolution is tested in 0.1 N HCl at 37°C with sampling at 15 min and 30 min. Published data for the dissolution specification of sialic acid immediate-release tablets is limited. Finished tablets are packed in aluminum-aluminum blisters because moisture uptake above 2.0% increases surface tackiness and slows disintegration. Elemental impurity risk is controlled according to ICH Q3D. Residual solvent levels are monitored by USP <467>. The terminal dosage form is an immediate-release oral tablet.

What Happens When Sialic Acid Is Subjected to Wet Granulation?

Aqueous wet granulation remains viable only within a narrow processing window. Sialic acid dissolves in water and creates solid bridges after drying. A binder solution of povidone K30 at 5 wt% concentration is introduced into the high-shear mixer. The binder amount is limited to 8–12% of dry granulate weight. Impeller speed is set at 150–200 rpm and chopper speed at 1000–1500 rpm. Wet massing time is limited to 20 min to prevent excessive solubilization and particle growth. Granule temperature is maintained below 45°C because sialic acid becomes discolored in hot acidic solution. The wet mass is passed through a 1.2 mm screen before drying. Drying is performed in a fluid-bed dryer with inlet air temperature at 55–65°C. Product temperature is kept below 40°C throughout the drying cycle. The endpoint is confirmed when loss on drying is below 2.0% by USP <921>. Dry granules are sized between 125 µm and 710 µm. Oversized granules are milled through a 0.8 mm screen at low speed. Wet granulation is not used when a fully crystalline API is required because partial amorphization increases hygroscopicity and lowers the glass transition of the dried granule. The final granules are stored with desiccant. The terminal dosage form is an oral tablet or granule. Published data for the long-term chemical stability of sialic acid wet granulations is limited.

Capsule Filling Without Lactose

Lactose-free capsule systems are selected to remove reducing-sugar interaction risk during stability. Sialic acid is filled into size 0 or size 1 capsules. Hard gelatin shells contain 13–16% water, which can transfer to sialic acid and cause powder caking. HPMC capsule shells with shell moisture below 7% are therefore preferred for moisture-sensitive sialic acid formulations. The capsule blend contains sialic acid at 40–60 wt%. A filler system of mannitol and pregelatinized starch in a 2:1 ratio is used to maintain flowability. Sodium stearyl fumarate is added at 1.0 wt% to replace magnesium stearate and reduce over-lubrication. Colloidal silicon dioxide at 0.5 wt% is pre-blended with sialic acid to reduce electrostatic adhesion to dosator surfaces. Filling is performed on an intermittent-motion capsule machine at 60,000 capsules/h. Tamping pin compression ratio is set to 1:1.2 to 1:1.4. Total fill weight for a size 0 capsule is 450 mg. Capsule weight variation is checked by USP <905>. Disintegration is tested by USP <701>. Relative humidity in the capsule filling suite is held at 25–30% RH. Final capsules are packed in HDPE bottles with heat-induction sealing and desiccant. Moisture ingress after 6 months is monitored by USP <921>. The terminal dosage form is an oral capsule.

For injectable lyophilized powder, the API is dissolved in Water for Injection at 2–8°C. The solution pH is adjusted to 6.5–7.0 with 1 M NaOH. This converts the free acid to the sodium salt in situ and reduces precipitation risk. Mannitol is used as a bulking agent at 3.0–5.0% w/v. The solution is filtered through a 0.22 µm sterilizing-grade polyethersulfone filter. The filtrate is filled into 5 mL Type I glass vials at a fill volume of 2.0 mL. Vials are partially stoppered and loaded into the lyophilizer. The freezing step is performed at -40°C for 2 h. Primary drying is carried out at shelf temperature -20°C and chamber pressure 0.20 mbar for 24 h. Secondary drying is performed at 25°C for 6 h. The resulting cake is inspected for collapse and cracking. Collapsed or cracked cakes are rejected because incomplete sublimation leaves residual moisture that destabilizes the API. Lyophilized sialic acid is hygroscopic. Headspace moisture is controlled below 1.0% by Karl Fischer titration using USP <921>. The powder is reconstituted with 2.0 mL sterile water. Reconstitution time should be less than 60 s. Particulate matter is tested by USP <788>. Bacterial endotoxins are tested by USP <85>. Sterility is tested by USP <71>. The lyophilized product is intended for intravenous or intramuscular injection after reconstitution. Long-term stability is evaluated under ICH Q1A(R2) conditions. Published data for the long-term stability of sialic acid lyophilized cakes is limited.

When Terminal Sterilization Is Replaced by Aseptic Filtration

When terminal sterilization is replaced by aseptic filtration, the manufacturing flow for liquid sialic acid injection must exclude any post-filtration heat step. The compounding vessel is jacketed and maintained at 5–10°C. The API is added slowly to WFI under nitrogen overlay. The solution pH is adjusted to 6.5±0.3 with sodium hydroxide. Mannitol is added to achieve final osmolality of 280–320 mOsm/kg. The solution is filtered through a 0.22 µm sterilizing-grade membrane. The filtrate is collected in a sterilized stainless-steel holding vessel. The hold time between sterile filtration and filling is limited to 4 h at 2–8°C. Aseptic filling is performed in an isolator or RABS classified as ISO 14644-1 Grade A. The fill volume is 2.0 mL or 5.0 mL per vial. In-line weight check is performed on 100% of filled units. The finished liquid product is stored at 2–8°C. Final specifications include pH 6.2–6.8, assay 95.0–105.0%, osmolality 280–320 mOsm/kg by USP <785>, particulate matter by USP <788>, bacterial endotoxins by USP <85>, and sterility by USP <71>. The terminal dosage form is a ready-to-use injectable solution.

Granule Sachet Lines and Moisture Barrier Requirements

Fluid-bed top-spray granulation is used for sialic acid stick-pack granules. The product bowl is charged with sialic acid, mannitol, and maltodextrin. Inlet air temperature is set to 60–65°C. Product temperature is maintained at 35–40°C. A spray solution of povidone K30 at 5 wt% is introduced at 8–12 g/min/kg of dry powder. Atomization air pressure is controlled between 1.2 bar and 1.8 bar. The resulting granules have a mean particle size of 200–300 µm. Drying continues in the same fluid-bed unit until loss on drying is below 1.5%. Cooled granules are screened through a 1.0 mm mesh. The final granulation is filled into stick packs made of polyester/aluminum foil/polyethylene laminate. Moisture vapor transmission rate is specified below 0.1 g/m²/day. This protects the sialic acid from humidity during storage. A horizontal form-fill-seal machine with auger filler is used. Fill weight is set between 1.0 g and 2.0 g per stick pack. Jaw sealing temperature is 160–180°C. Seal integrity is tested by vacuum leak at -0.6 bar for 3 min. The finished stick pack is an oral granule dosage form reconstituted in water before administration.

Dose flexibility for pediatric or dysphagic patients requires an oral liquid. The solution is compounded with sialic acid in purified water at 5–25°C. The pH is adjusted to 5.5–6.5 with citrate buffer. This pH range minimizes free acid precipitation and reduces acid-catalyzed degradation. A preservative system of methylparaben and propylparaben is added only after pH adjustment to avoid ionization shifts. The bulk solution is filtered through a 0.45 µm clarifying filter. It is filled into amber glass bottles with child-resistant closures. Fill volume is 100 mL or 200 mL. The finished solution is stored at 2–8°C after first opening. Microbial limits are tested by USP <61> and USP <62>. Assay is performed by high-performance liquid chromatography with UV detection. The terminal dosage form is an oral liquid.